Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients

Treatment options for patients with metastatic soft tissue sarcomas are limited. Re-challenge with a previously successful gemcitabine-based regimen is common. There are no published data to support this practice. We conducted a retrospective search to identify patients re-challenged with gemcitabin...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-01, Vol.39 (1), p.347-351
Main Authors: Sebio, Ana, Constantinidou, Anastasia, Benson, Charlotte, Antoniou, Georgios, Messiou, Christina, Miah, Aisha, Zaidi, Shane, Petruckevitch, Ann, Al-Muderis, Omar, Thway, Khin, VAN DER Graaf, Winette T, Jones, Robin L
Format: Article
Language:English
Subjects:
Chemotherapy
Gemcitabine
Identification methods
Metastases
Metastasis
Patients
Survival
Tissues
Toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment options for patients with metastatic soft tissue sarcomas are limited. Re-challenge with a previously successful gemcitabine-based regimen is common. There are no published data to support this practice. We conducted a retrospective search to identify patients re-challenged with gemcitabine-based chemotherapy (GBC) from 2003 to 2015. Twenty-nine patients re-challenged with gemcitabine were identified. The response rate for initial GBC was 55% (n=15) and for re-challenge GBC 26% (n=6). The median progression-free survival was 11.1 months (95%CI=7.2-11.9) for initial GBC and 5.3 months (95%CI=2.0-7.5) for re-challenge GBC. Overall survival following gemcitabine re-challenge was 12.2 months (95%CI=7.0-18.2). Twelve out of 26 evaluable patients (46%) treated with re-challenge GBC experienced grade 3-4 adverse events (CTCAE 4.03) with 31% (n=8) of patients requiring dose reduction. In selected patients, gemcitabine re-challenge can be considered in advanced sarcomas, however, this approach is associated with toxicity.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13118